ENDPOINTS

Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences

Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a Claudin18.2-targeted antibody-drug conjugate from Evopoint Biosciences. The Suzhou-based biotech could receive another $70 million ...

May 30, 2025 - 00:34
 0
Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences
Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a Claudin18.2-targeted antibody-drug conjugate from Evopoint Biosciences. The Suzhou-based biotech could receive another $70 million ...
Read More

Tags:

Previous Article

The A2Z NACS To CCS & CCS To NACS Adapters — CleanTechnica Tested

Next Article

Beware beaches near river mouths: the air may not be fresh

Related Posts

MD Anderson targets $250M for second cancer biotech fund

MD Anderson targets $250M for second cancer biotech fund

May 28, 2025  0

The ‘MAHA report’: What it says about vaccines, medicine and the pharma industry

The ‘MAHA report’: What it says about vaccines, medicin...

May 22, 2025  0

#ASGCT25: Lower conference attendance mirrors challenged cell and gene field

#ASGCT25: Lower conference attendance mirrors challenge...

May 16, 2025  0